The Effect of AL Amyloidosis

Video

Heather Landau, M.D., Assistant Attending Physician at the Memorial Sloan Kettering Cancer Center, explains AL Amyloidosis. In this video, she describes in detail the clinical definition of the disease, what organs are affected, and early presentation.

Heather Landau, M.D., Assistant Attending Physician at the Memorial Sloan Kettering Cancer Center, explains AL - or Light Chain - Amyloidosis. In this video, she describes in detail the clinical definition of the disease, what organs are affected, and early presentation.

Landau: Light chain amyloidosis is a plasm cell disorder that starts in the bone marrow. The culprit is a pathologic plasma cell that goes awry and makes abnormal proteins that mis-fold and deposit in organs, causing organ damage. The factory that makes the light-chains is a pathologic plasma cell. The issue is that once these light chains are produced they can deposit as a substance called amyloid and disrupt tissue structure and function mainly in the heart, GI tract, the liver, kidneys, soft tissues, and the nervous system. By and large the kidneys and the heart are the most commonly affected organs. Early presentation is different depending on which organ is affected.

The patients with kidney disease, if we pick them up early, are asymptomatic and they usually just get picked up by a routine urinalysis that is being done for something else. The problem with AL amyloidosis is It mimics common conditions, such as patients who feel unwell and short of breath and other non-specific symptoms, that are more representative of less rare disease than amyloidosis. So, when someone goes to their internist and says I’m tired and short of breath they look for cardiac disease in the way the general population has cardiac disease, like schemic cardiac disease or pulmonary disease. I’ve even seen patients have sinus surgery when they weren’t breathing well when this was all cardiac amyloid.

Most of the patients are suspected or have been diagnosed when they get to me. We did a survey with the amyloid research consortium and found over 400 patients have seen an average of four different doctors, the median number of specialists, before they get a diagnosis, often times going unrecognized.

Related Videos
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease
Mercedes Martinez, MD: Treatment Strategies for Autoimmune Hepatitis
© 2024 MJH Life Sciences

All rights reserved.